Photo Rounds

Blue-black hyperpigmentation on the extremities

Author and Disclosure Information

 

References

Antimalarials. Chloroquine, hydroxychloroquine, and quinacrine can cause blue-black skin hyperpigmentation in as many as 25% of patients. Common locations include the shins, face, oral mucosa, and subungual skin. This hyperpigmentation rarely fully resolves.2

Amiodarone. Hyperpigmentation secondary to amiodarone use typically is slate-gray in color and involves photoexposed skin. Patients should be counseled that pigmentation may—but does not always—fade with time after discontinuation of the drug.2

Heavy metals. Argyria results from exposure to silver, either ingested orally or applied externally. A common cause of argyria is ingestion of excessive amounts of silver-­containing supplements.3 Affected patients present with diffuse slate-gray discoloration of the skin.

This case underscores the importance of routinely reassessing patients’ understanding of their medications and treatment plans.

Other metals implicated in skin hyperpigmentation include arsenic, gold, mercury, and iron. Review of all supplements and herbal remedies in patients presenting with skin hyperpigmentation is crucial.

Bleomycin is a chemotherapeutic agent with a rare but unique adverse effect of inducing flagellate hyperpigmentation that favors the chest, abdomen, or back. This may be induced by trauma or scratching and is often transient. Hyperpigmentation can occur secondary to either intravenous or intralesional injection of the medication.2

Continue to: In addition to medication...

Pages

Recommended Reading

Melanoma mortality rates fell in 2010s as new therapies took hold
MDedge Family Medicine
Erythrasma
MDedge Family Medicine
Teen with hyperpigmented skin lesions
MDedge Family Medicine
A 17-year-old male was referred by his pediatrician for evaluation of a year-long rash
MDedge Family Medicine
Ustekinumab matches TNF inhibitors for psoriatic arthritis in 3-year, real-world study
MDedge Family Medicine
Dupilumab significantly improves markers of AD severity in pediatric patients
MDedge Family Medicine
FDA approves Idacio as eighth adalimumab biosimilar in U.S.
MDedge Family Medicine
FDA will review pediatric indication for roflumilast cream
MDedge Family Medicine
Macules and abdominal pain
MDedge Family Medicine
Incidental skin finding
MDedge Family Medicine